Literature DB >> 187961

Influence of papaverine derivatives on phosphodiesterase activity, cyclic 3',5'-AMP levels and relaxing effect on rabbit ileum.

S F Berndt, H U Schulz, K Stock.   

Abstract

The correlations between the relaxing effect of papaverine derivatives, inhibition of low Km-phosphodiesterase (cAMP-PDE = EC 3.1.4.17) activity and cyclic 3',5'-AMP (cAMP) levels in isolated rabbit ileum were investigated. There was a strong correlation between the relaxing effect, inhibition of PDE activity and cAMP content for eupaverine, ethylpapaverine and papaverine. Eupaverine was the most effective relaxing agent (I50 = 7.5 muM) and the most potent inhibitor of PDE activity (Ki = 0.6 muM), followed by ethylpapaverine (I50 = 10 muM;Ki 0.8 muM) and papaverine (I50 = 20 muM;Ki = 2 muM). In contrast, there was a strong relaxing effect (I50 = 6 muM) but only slight inhibition of PDE activity (Ki = 350 muM) by tetrahydropapaveroline (THP). The adenylate cyclase stimulating effect of THP which was shown by others is most likely the reason for comparatively higher cAMP levels, which were found to be elevated about seven times over basal levels of 0.35 nmoles/g wet weight, and effective relaxation. Relaxation could be induced by exogenously added cAMP (I50 = 45 muM) and dibutyryl-cAMP (I50 = 450 muM). Our results support the assumption that smooth muscle relaxation in rabbit ileum is mediated by cAMP. Some of these observations have been published in abstract form (Schulz and Berndt, 1972).

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 187961     DOI: 10.1007/bf00508395

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  21 in total

1.  Adenyl cylase. I. Distribution, preparation, and properties.

Authors:  E W SUTHERLAND; T W RALL; T MENON
Journal:  J Biol Chem       Date:  1962-04       Impact factor: 5.157

2.  Proceedings: Experiments to classify the beta-receptor-stimulating properties of tetrahydropapaveroline.

Authors:  I B Armah; V Jakovljevic; P Ochlich; O Rohte
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1975       Impact factor: 3.000

3.  Cyclic AMP and calcium ions in mechanical and metabolic responses of smooth muscles; influence of some hormones and drugs.

Authors:  R G Andersson
Journal:  Acta Physiol Scand Suppl       Date:  1972

4.  Cyclic AMP and smooth muscle function.

Authors:  L Triner; G G Nahas; Y Vulliemoz; N T Overweg; M Verosky; D V Habif; S H Ngai
Journal:  Ann N Y Acad Sci       Date:  1971-12-30       Impact factor: 5.691

5.  Inhibition of cyclic-3',5'-nucleotide-phosphodiesterase as a possible mode of action of papaverine and similarly acting drugs.

Authors:  W R Kukovetz; G Pöch
Journal:  Naunyn Schmiedebergs Arch Pharmakol       Date:  1970

6.  [Influence of cardio- and vasoactive substances on phosphodiesterase activity].

Authors:  G Pöch; H Juan; W R Kukovetz
Journal:  Naunyn Schmiedebergs Arch Pharmakol       Date:  1969

7.  Cyclic phosphodiesterase activity and the action of papaverine.

Authors:  L Triner; Y Vulliemoz; I Schwartz; G G Nahas
Journal:  Biochem Biophys Res Commun       Date:  1970-07-13       Impact factor: 3.575

8.  Cyclic 3'5'-AMP, its dibutyryl derivative and theophylline effects on the rat portal vein in vitro.

Authors:  F Berti; C Sirtori; M M Usardi
Journal:  Arch Int Pharmacodyn Ther       Date:  1970-04

9.  Relaxant effect of cyclic adenosine 3',5'-monophosphate on the isolated rabbit ileum.

Authors:  T S Kim; J Shulman; R A Levine
Journal:  J Pharmacol Exp Ther       Date:  1968-09       Impact factor: 4.030

10.  Effect of tetrahydroisoquinoline derivatives on the adenylate cyclases of the caudate nucleus (dopamine-type) and erythrocyte (beta-type) of the rat.

Authors:  H Sheppard; C R Burghardt
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1974-07
View more
  1 in total

Review 1.  Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson's Disease?

Authors:  Dominic Ngima Nthenge-Ngumbau; Kochupurackal P Mohanakumar
Journal:  Mol Neurobiol       Date:  2017-01-06       Impact factor: 5.590

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.